FIT Should Replace FOBT for Colorectal Cancer Screening
No, guaiac-based FOBT should not replace FIT—rather, FIT should replace FOBT as the preferred stool-based screening test for colorectal cancer. FIT demonstrates superior sensitivity for both cancer and advanced adenomas, requires no dietary restrictions, needs fewer samples, and achieves higher patient participation rates. 1
Why FIT is Superior to FOBT
Detection Performance
FIT detects cancer with 79-82% sensitivity compared to only 64% for high-sensitivity guaiac FOBT, representing a clinically meaningful improvement in cancer detection that directly impacts mortality. 1
For advanced adenomas, FIT achieves 23-42% sensitivity versus only 7-41% for guaiac FOBT, with most comparative studies showing FIT detecting 2-2.5 times more advanced neoplasia. 1, 2
Both tests maintain comparable high specificity (FIT: 90-94%, guaiac FOBT: 87-99%), meaning FIT's superior sensitivity does not come at the cost of excessive false positives. 1
Technical and Practical Advantages
FIT requires only 1-2 stool samples versus 6 specimens (2 from each of 3 consecutive bowel movements) for guaiac FOBT, dramatically simplifying the testing process. 1
FIT requires no dietary restrictions (no avoidance of red meat, vegetables, or vitamin C), while guaiac FOBT mandates a 3-day dietary restriction period that reduces patient compliance. 1
FIT is unaffected by medications including NSAIDs, aspirin, and iron supplements, whereas these can cause false results with guaiac FOBT. 3, 4
FIT specifically detects human globin protein, making it selective for lower GI bleeding, while guaiac FOBT's chemical reaction detects any peroxidase activity, leading to dietary false positives. 3
Patient Participation and Real-World Impact
FIT achieves 10-20% higher participation rates than guaiac FOBT in screening programs, which is critical since screening only works if patients complete it. 3, 5
In a large Veterans Administration study, replacing guaiac FOBT with FIT increased screening completion from 33.4% to 42.6% (absolute increase of 9.2%), with the number needed to invite being only 11 to achieve one additional completed test. 5
FIT detected advanced neoplasia in 0.79% versus 0.28% for guaiac FOBT in the same population, meaning 196 patients needed to be invited to identify one additional case of advanced neoplasia. 5
Mortality Benefit Evidence
Both tests reduce colorectal cancer mortality when used annually: guaiac FOBT reduces mortality by 15-33% in randomized trials, while FIT demonstrates a 10% mortality reduction (RR 0.90,95% CI 0.84-0.95) in a large Taiwanese cohort of over 1.1 million individuals. 1
The mortality benefit requires annual testing with either modality—single or sporadic testing provides inadequate protection. 1
Current Guideline Recommendations
NCCN Guidelines (2018)
The NCCN explicitly states that FIT is superior to guaiac FOBT in both participation rates and detection of advanced adenomas and colorectal cancer, based on extensive literature analysis. 1
High-sensitivity guaiac FOBT can be used as an alternative to FIT only when FIT is unavailable, acknowledging that guaiac FOBT has proven mortality benefit but is not the preferred option. 1
Only high-sensitivity guaiac tests (sensitivity >70%, specificity >90%) are acceptable—older low-sensitivity versions like unrehydrated Hemoccult II should be discontinued. 1
Other Major Guidelines
The US Multi-Society Task Force on Colorectal Cancer provides a strong recommendation for FIT over guaiac FOBT based on high-quality evidence. 3
The American College of Physicians recommends FIT or high-sensitivity guaiac FOBT every 2 years, listing FIT first as the preferred option. 1
The USPSTF includes both annual FIT and annual guaiac FOBT as acceptable options, though the evidence base increasingly favors FIT. 1
Clinical Implementation Algorithm
When to Use FIT (Preferred)
Order FIT as first-line for all average-risk adults aged 50-75 years requiring stool-based colorectal cancer screening. 1, 3
No preparation required: patients continue all medications (including iron, NSAIDs, anticoagulants) and maintain normal diet. 3, 4
Collect 1-2 spontaneously passed stool samples (never from digital rectal examination). 3
Any positive FIT requires diagnostic colonoscopy within 60 days—never repeat stool testing. 3
When Guaiac FOBT May Be Used
Only when FIT is genuinely unavailable due to supply, cost, or institutional limitations. 1
Must use high-sensitivity version (e.g., Hemoccult SENSA, not Hemoccult II). 1
Requires patient counseling about 3-day dietary restrictions (avoid red meat, poultry, fish, certain vegetables) and 7-day medication restrictions (avoid NSAIDs >1 adult aspirin dose/day). 6
Collect 2 samples from each of 3 consecutive bowel movements (6 total specimens). 1, 6
Critical Pitfalls to Avoid
Never perform single-sample FOBT during digital rectal examination—this has <10% sensitivity and is explicitly not recommended for screening. 1, 3
Never repeat stool testing after a positive result—any positive stool test mandates colonoscopy, not another stool test. 1, 3
Do not use FIT in patients with iron deficiency anemia—these patients require direct colonoscopy (FIT sensitivity drops to 58% in this population). 4
Ensure annual testing—the mortality benefit of stool-based screening depends on annual repetition; sporadic testing is inadequate. 1
FIT has only 5% sensitivity for sessile serrated polyps—it is not a comprehensive screening test for all colorectal neoplasia. 3
Cost Considerations
FIT costs approximately $20 per test versus $6-28 for guaiac FOBT, but the higher completion rates and superior detection make FIT cost-effective. 1
Medicare and most insurers now reimburse FIT, removing the historical financial barrier that previously favored guaiac FOBT. 1
Bottom Line for Clinical Practice
Replace guaiac FOBT with FIT in your practice. The superior sensitivity (82% vs 64% for cancer), lack of dietary restrictions, simpler collection (1-2 samples vs 6), and higher patient participation (10-20% increase) make FIT the clear choice for stool-based colorectal cancer screening. Reserve high-sensitivity guaiac FOBT only for situations where FIT is truly unavailable, and never use low-sensitivity guaiac tests or single-sample office-based testing. 1, 3, 5